Clinical trial
EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
NCT03350542 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Lead sponsor
- Boston Scientific Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 12, 2018
- Completion date
- January 8, 2021
- Enrollment
- 100 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.